These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Tawfik MO; Bryuzgin V; Kourteva G; Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835 [TBL] [Abstract][Full Text] [Related]
23. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Berliner MN; Giesecke T; Bornhövd KD Clin J Pain; 2007; 23(6):530-4. PubMed ID: 17575494 [TBL] [Abstract][Full Text] [Related]
24. Transdermal fentanyl: informed prescribing is essential. Ross JR; Quigley C Eur J Pain; 2003; 7(5):481-3. PubMed ID: 12935801 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190 [TBL] [Abstract][Full Text] [Related]
27. [Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy]. Dtsch Med Wochenschr; 1995 Oct; 120(41 Suppl):1-4. PubMed ID: 9022357 [No Abstract] [Full Text] [Related]
28. Treatment of cancer pain with transdermal fentanyl. Gourlay GK Lancet Oncol; 2001 Mar; 2(3):165-72. PubMed ID: 11902567 [TBL] [Abstract][Full Text] [Related]
29. [Transdermal fentanyl dependency in the treatment of chronic pain in the elderly: presentation of a case]. Calle Egusquiza A; Planas Domingo J; Farriols Danés C Rev Esp Geriatr Gerontol; 2011; 46(3):179. PubMed ID: 21477893 [No Abstract] [Full Text] [Related]
30. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339 [TBL] [Abstract][Full Text] [Related]
31. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087 [TBL] [Abstract][Full Text] [Related]
32. [Transdermal fentanyl: a new tool for pain therapy in pediatric oncology]. Cappelli C; Reale G; Marucci G; Clerico A Clin Ter; 2008; 159(4):257-60. PubMed ID: 18776983 [TBL] [Abstract][Full Text] [Related]
33. Transdermal fentanyl: caution in the use of high doses. Botterman J; De Meester C; Eeckhaut K Palliat Med; 2004 Oct; 18(7):663. PubMed ID: 15540677 [No Abstract] [Full Text] [Related]
34. Fentanyl transdermal system: market withdrawal. Exposes patients to a risk of overdose. The market withdrawal, due to a manufacturing defect, is more than welcome. Prescrire Int; 2009 Jun; 18(101):110. PubMed ID: 19637419 [No Abstract] [Full Text] [Related]
35. Sticking to the safe side with fentanyl patches. D'Arcy Y Nursing; 2009 Mar; 39(3):62-3. PubMed ID: 19247136 [No Abstract] [Full Text] [Related]
36. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Portenoy RK; Southam MA; Gupta SK; Lapin J; Layman M; Inturrisi CE; Foley KM Anesthesiology; 1993 Jan; 78(1):36-43. PubMed ID: 8424569 [TBL] [Abstract][Full Text] [Related]
37. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070 [TBL] [Abstract][Full Text] [Related]
38. Fentanyl transdermal system. Pain management at home. Woodroffe MA; Hays H Can Fam Physician; 1997 Feb; 43():268-72. PubMed ID: 9040914 [TBL] [Abstract][Full Text] [Related]
39. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070 [TBL] [Abstract][Full Text] [Related]